Actively Recruiting
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
Led by University of Alabama at Birmingham · Updated on 2026-04-23
200
Participants Needed
1
Research Sites
207 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.
CONDITIONS
Official Title
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 to 89 years of age
- Admitted to University of Alabama at Birmingham main hospital with symptoms or signs of minor ischemic stroke or high-risk transient ischemic attack
- Eligible to receive dual antiplatelet therapy load and presented within 66 hours of last known well
You will not qualify if you...
- Diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability, or large vessel disease with culprit vessel stenosis of 50% or more
- Prescribed anticoagulation before stroke
- Treated with intravenous thrombolysis
- Treated with mechanical thrombectomy
- Missing NIH Stroke Scale score
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Actively Recruiting
Research Team
E
Ekaterina Bakradze, MD
CONTACT
N
Nita Limdi, PharmD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here